Drug ID:Drug184
Drug Name:GLPG3970
CID:146273261
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT04577794
Molecular Formula:C25H27F3N4O4
Molecular Weight:504.5 g/mol
Isomeric SMILES:COC1=CC(=CC2=C1C(=O)N(CC2)CC(F)(F)F)C3=CN=C4N3C=CC(=C4)OCCN5CCOCC5
Synonyms:GLPG3970; 2403733-82-2; GLPG-3970; UA6B2TI4MO; UNII-UA6B2TI4MO; 8-methoxy-6-{7-[2-(morpholin-4-yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one; CHEMBL5393771; 1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-(7-(2-(4-morpholinyl)ethoxy)imidazo(1,2-a)pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-; 8-Methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one; SCHEMBL21591149
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1309 146273261 8-Methoxy-6-{7-[2-(morpholin-4-yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one 23235 SIK2 Homo sapiens (human) Inhibition
dt1310 146273261 8-Methoxy-6-{7-[2-(morpholin-4-yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one 23387 SIK3 Homo sapiens (human) Inhibition

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT04577794 A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis PHASE2 COMPLETED Galapagos NV Ulcerative Colitis DRUG: GLPG3970|DRUG: Placebo Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years PHASE3 RECRUITING Ardelyx Irritable Bowel Syndrome With Constipation (IBS-C) DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… Details
NCT05633706 Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis NULL RECRUITING Nimble Science Ltd. Irritable Bowel Syndrome|Crohn Disease|Celiac Dis… DEVICE: fluid biopsy capsule Details
NCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome PHASE3 RECRUITING Biocodex IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… Details
NCT05602116 ASC - Autism Study PHASE1 COMPLETED Cell to Cure ApS Autism Spectrum Disorder|Gastrointestinal Dysfunc… DRUG: Adipose tissue derived mesenchymal stromal/… Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05573685 Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training NA COMPLETED Click Therapeutics, Inc. Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… DEVICE: DiNaMo Study App|DEVICE: Placebo App Details
NCT05536440 A Study to Learn About Study Medicine Called PF-07261271 in Healthy People PHASE1 COMPLETED Pfizer Healthy DRUG: PF-07261271|DRUG: Placebo Details
NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease PHASE3 RECRUITING Eli Lilly and Company Crohn's Disease DRUG: Mirikizumab Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05466890 Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) PHASE2 ACTIVE_NOT_RECRUITING Palatin Technologies, Inc Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… DRUG: PL8177 Placebo|DRUG: PL8177 Details
NCT05451433 The Effect of Saccharomyces Boulardii in Clinical Presentation and Quality of Life Patient With IBS NA UNKNOWN Fakultas Kedokteran Universitas Indonesia Irritable Bowel Syndrome DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placebo Details
NCT05377580 A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis PHASE2 COMPLETED Innovent Biologics (Suzhou) Co. Ltd. Ulcerative Colitis (UC) DRUG: Period 1 IBI112 Placebo|DRUG: Period 2 IBI1… Details
NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis PHASE2 TERMINATED Vedanta Biosciences, Inc. Ulcerative Colitis|Colitis, Ulcerative BIOLOGICAL: VE202|DRUG: Vancomycin Oral Capsule|O… Details
NCT07145580 Combined Lactulose H2-breath Test With Abdominal Imaging NULL RECRUITING Klinik Arlesheim Food Intolerance Syndromes|Small Intestinal Bacte… None Details
NCT05291689 A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC PHASE2 COMPLETED Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Inflammatory Bowel Diseases|Colitis, Ulcerative DRUG: MORF-057 Details
NCT05271838 Protein and Magnesium in Ulcerative Colitis NA UNKNOWN University of Aarhus Inflammatory Bowel Diseases|Colitis, Ulcerative|M… DIETARY_SUPPLEMENT: Magnesium acetate mixture (30… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations